161 related articles for article (PubMed ID: 36093262)
1. Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort.
Bi Z; Cao Y; Liu C; Gui M; Lin J; Zhang Q; Li Y; Ji S; Bu B
Ther Adv Chronic Dis; 2022; 13():20406223221122538. PubMed ID: 36093262
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
3. Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis.
Caifeng S; Jingsheng Z; Yi L; Xueshi H; Zhanyou W; Haiou P; Wenjun Q
J Tradit Chin Med; 2022 Oct; 42(5):810-817. PubMed ID: 36083490
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.
Zhang KY; Duan WW; Luo YB; Li Y; Hu J; Yang H
Orphanet J Rare Dis; 2024 Jan; 19(1):19. PubMed ID: 38243274
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Improvement in a Chinese Cohort of Glucocorticoid-Resistant Childhood-Onset Myasthenia Gravis Patients Treated With Tacrolimus.
Bi Z; Cao Y; Lin J; Zhang Q; Liu C; Gui M; Bu B
Front Neurol; 2022; 13():820205. PubMed ID: 35211085
[TBL] [Abstract][Full Text] [Related]
6. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study.
Ponseti JM; Gamez J; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Armengol M
Curr Med Res Opin; 2007 Jun; 23(6):1269-78. PubMed ID: 17559724
[TBL] [Abstract][Full Text] [Related]
7. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
8. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Wu H; Chen L; Zhou X; Wu Y; Yan Y; Zhu Y; Zhao C; Xue Q
J Neuroimmunol; 2022 Nov; 372():577955. PubMed ID: 36054935
[TBL] [Abstract][Full Text] [Related]
9. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
10. Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis.
Vemuri D; Garuda BR; Gopi S; Kumar TS; Kumari UA
Ann Indian Acad Neurol; 2020; 23(2):215-219. PubMed ID: 32189865
[TBL] [Abstract][Full Text] [Related]
11. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.
Nishida Y; Takahashi YK; Kanai T; Nose Y; Ishibashi S; Sanjo N; Uzawa A; Oda F; Ozawa Y; Kuwabara S; Noguchi E; Suzuki S; Nakahara J; Suzuki N; Ogawa T; Yokoyama K; Hattori N; Konno S; Fujioka T; Kawaguchi N; Hatanaka Y; Sonoo M; Kaneko J; Ogino M; Nishiyama K; Nomura K; Yokota T
Eur J Neurol; 2020 Jan; 27(1):100-104. PubMed ID: 31309642
[TBL] [Abstract][Full Text] [Related]
12. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
Zhang Y; Zhang M; Zhang L; Zhou S; Li W
J Clin Neurosci; 2023 Oct; 116():93-98. PubMed ID: 37669613
[TBL] [Abstract][Full Text] [Related]
14. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma.
De Rosa A; Fornili M; Maestri Tassoni M; Guida M; Baglietto L; Petrucci L; Chella A; Melfi F; Lucchi M; Ricciardi R
Thorac Cancer; 2021 Jan; 12(1):106-113. PubMed ID: 33142021
[TBL] [Abstract][Full Text] [Related]
15. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
[TBL] [Abstract][Full Text] [Related]
16. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M
Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.
Huang X; Li Y; Feng H; Chen P; Liu W
Front Neurol; 2018; 9():77. PubMed ID: 29535672
[TBL] [Abstract][Full Text] [Related]
19. Plasma exchange for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2002; 2002(4):CD002275. PubMed ID: 12519572
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
